Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1391&sort=principal_investigator
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=principal_investigator", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1419&sort=principal_investigator", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=principal_investigator", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1390&sort=principal_investigator" }, "data": [ { "type": "Grant", "id": "15588", "attributes": { "award_id": "5I01RX004572-03", "title": "Modifying Adiposity Through Behavioral Strategies to Improve COVID-19 Rehabilitation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2023-11-01", "end_date": "2029-10-31", "award_amount": null, "principal_investigator": { "id": 32034, "first_name": "KATHLEEN A", "last_name": "GRIFFITH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26754, "first_name": "ALICE S.", "last_name": "RYAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1532, "ror": "https://ror.org/036a0e562", "name": "Baltimore VA Medical Center", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Findings of post-acute sequelae of Post-COVID Conditions (PCC) manifestations of fatigue, pain, dyspnea, and muscle weakness, provide a strong rationale for rehabilitation; yet few formal studies exist and the effects of severe acute respiratory syndrome coronavirus-2 infection on function are not well described. Notably, two- thirds of Veterans are overweight and obese, rendering excess adiposity a significant risk factor and a high- priority area related to PCC prevention and care. Obesity increases the risk of severe illness in Veterans recovering from PCC, but how it does so is not fully understood. Recent research suggests that excess adipose tissue is associated with adverse changes in adipose cellular function, and that these variations may be involved in the biology of aging and the etiology of aging- related diseases. Adipose tissue contains cells that have undergone cellular senescence, which induces inflammation, cytotoxicity, and metabolic dysfunction in other cells and tissues. However, the precise role of adipose tissue cellular composition on PCC recovery is limited. Thus, we propose to evaluate the role of obesity and PCC on physical functioning, health-related quality of life (HRQOL), and systemic and adipose tissue inflammatory and cellular senescence profiles in ethnically diverse older Veterans from the Audie Murphy (San Antonio) and Baltimore VA Medical Centers. Further, we propose a randomized controlled trial to determine whether a reduction in body weight and increased physical function by a weight loss intervention (WL), including dietary modification and exercise, in obese Veterans with PCC will reduce systemic and adipose tissue inflammation and senescence, which will have important implications for PCC recovery. We will pursue the following aims: Aim 1: To compare physical function, body composition, HRQOL, PCC symptoms, and adipose tissue molecular profiling in four cohorts of Veterans at baseline: lean PCC naïve, lean with PCC, obese PCC naïve, and obese with PCC (N=150). Aim 2: To compare in Veterans with obesity: a) a 12-week randomized WL vs. weight stability (WS) intervention (30/group) on physical function, body composition, HRQOL, and PCC symptoms together with changes in the global molecular profile in adipose tissue in Veterans with PCC and b) the WL intervention in PCC naïve vs. with PCC (N=30/group) on these outcomes. Older (55-80 years) men and women Veterans will be recruited. We will perform a standard functional battery (maximal aerobic capacity [VO2max; primary outcome], usual gait speed, six min walk distance, timed up and go, and handgrip strength), body composition (dual energy x-ray absorptiometry and computed tomography scans), HRQOL (NIH PROMIS-57), and PCC symptoms (COVID-19 Yorkshire Rehabilitation Scale [C19-YRS]) and adipose tissue will be collected. Further, we will test, in a randomized controlled trial, the hypothesis that a WL intervention, compared to weight stability (WS), improves physical function, body composition, and HRQOL and reduces inflammation and senescent cell burden and to a similar extent as the PCC naïve group with obesity. A deeper understanding of the relationship between adipose tissue and PCC will likely reveal factors that predispose to or protect against aging-related functional declines. Moreover, a better understanding of the effects of a lifestyle intervention on the molecular profile of adipose tissue will help to determine how changes in adipose tissue contribute to PCC and PCC recovery. Lastly, this research will provide important mechanistic insights into how cellular senescence influences the pathophysiology of physical, mental, and social dysfunction in older Veterans. Our findings could provide evidence-based recommendations to promote this type of intervention in Veterans recovering from PCC.", "keywords": [ "2019-nCoV", "Acute", "Adipose tissue", "Aerobic", "Area", "Baltimore", "Behavioral", "Biological Assay", "Biology of Aging", "Body Composition", "Body Weight", "COVID-19", "COVID-19 impact", "COVID-19 prevention", "Caring", "Cell Aging", "Cell Cycle Arrest", "Cell Physiology", "Cells", "Chronic", "Diet Modification", "Dual-Energy X-Ray Absorptiometry", "Dyspnea", "Etiology", "Exercise", "Fatigue", "Fatty acid glycerol esters", "Functional disorder", "Gait speed", "Health", "Individual", "Inflammation", "Inflammatory", "Intervention", "Intramuscular", "Laboratories", "Life Style", "Long COVID", "Medical center", "Metabolic dysfunction", "Molecular Profiling", "Muscle Weakness", "Obesity", "Outcome", "Overweight", "Oxidative Stress", "Pain", "Participant", "Patient Self-Report", "Phenotype", "Physical Function", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Predisposing Factor", "Prevention", "Psyche structure", "Randomized", "Randomized Controlled Trials", "Recovery", "Rehabilitation therapy", "Reporting", "Research", "Risk", "Risk Factors", "Role", "SARS-CoV-2 infection", "Sampling", "Scanning", "Symptoms", "Testing", "Thinness", "Tissue Banks", "Tissues", "United States National Institutes of Health", "VO2max", "Variant", "Veterans", "Visceral fat", "Walking", "Weight", "Woman", "X-Ray Computed Tomography", "aging related", "aging related disease", "clinical implementation", "cohort", "cytotoxicity", "disability", "ethnic diversity", "evidence based guidelines", "functional decline", "health related quality of life", "improved", "innovation", "insight", "lifestyle intervention", "men", "novel", "persistent symptom", "pharmacologic", "physical conditioning", "post-COVID conditions", "post-COVID-19", "primary outcome", "recruit", "response", "senescence", "senescence associated secretory phenotype", "senescent cell", "social deficits", "weight loss intervention" ], "approved": true } }, { "type": "Grant", "id": "15440", "attributes": { "award_id": "3R01MD019027-02S1", "title": "Factors Influencing Pediatric Asthma into Adulthood (FIPA2)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 27240, "first_name": "UTIBE RONALD", "last_name": "Bickham-Wright", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-25", "end_date": "2028-04-30", "award_amount": 120454, "principal_investigator": { "id": 32035, "first_name": "LYLE G", "last_name": "BEST", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 9754, "first_name": "Esther", "last_name": "Erdei", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 761, "ror": "", "name": "UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR", "address": "", "city": "", "state": "NM", "zip": "", "country": "United States", "approved": true } ] }, { "id": 32036, "first_name": "Dara", "last_name": "Torgerson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2543, "ror": "", "name": "MISSOURI BREAKS RESEARCH, INC.", "address": "", "city": "", "state": "SD", "zip": "", "country": "United States", "approved": true }, "abstract": "A. Summary of Funded Parent Grant: Factors Influencing Pediatric Asthma into Adulthood (R01MD019027) The prevalence of asthma among American Indian (AI) children is 9.3% as compared to 5.5% in non- Hispanic White children. Asthma disparities become even more pronounced into adulthood, with AI adults having the highest prevalence of asthma as compared to all other racial/ethnic groups in the US, with 60% uncontrolled. Asthma is influenced by social and environmental factors (SEF) including adverse childhood events (ACEs), tobacco smoke, and everyday life stressors that may alter immunological state. ACEs in particular, including abuse, neglect, and household challenges have been associated with immune dysregulation, may have implications for clinical outcomes of respiratory viral infections in children that have been linked to asthma and persistent respiratory symptoms. For example, Infants who develop severe RSV bronchiolitis in the first year of life are more likely to develop asthma, and children with asthma are at increased risk of experiencing complications from respiratory viral infections due to SARS-CoV-2, respiratory syncytial virus (RSV), influenza, and rhinovirus C. In the Factors Influencing Pediatric Asthma (FIPA) study including children from a Northern Plains American Indian community, we found children with asthma experienced an increased clinical burden from RSV infection and had lower levels of serum RSV-specific Immunoglobulin G (IgG) than children without asthma, indicative of immune suppression or dysfunction. However, the complex interplay between social, environmental and immunological response to viral respiratory infections remains largely unknown, and these factors have not been investigated among AI children with respect to their influence on immunological response and asthma development and control of asthma symptoms. In this continued AI community-focused study, we will test the hypothesis that social and environmental factors contribute to asthma susceptibility through stress-induced immune dysregulation, including the alteration of immunological response to viral respiratory infections. We will also investigate the role of viral respiratory infections and SEF on asthma control, including frequency of symptoms, exacerbations, ER visits/hospitalizations, and use of asthma medications. Aim 1: Identify social and environmental factors (SEF) that contribute to asthma susceptibility, asthma control, and long-term respiratory health in American Indian children. We will follow-up on our previously NIMHD-funded case/control study of 324 children recruited between the ages of 6-17 from 2013- 2017 as they transition into adulthood (now ages 11-27). We will recontact original study participants, evaluating their current asthma status to investigate the role of age and gender on long-term respiratory health including current asthma and asthma control. We will also expand our study to 400 new participants with and without asthma between the ages of 6-17, including Tribal members living in Rapid City, SD, and offspring of original study participants (~30% of original study participants have since become parents). We will obtain detailed measures of SEF, and retrospective information on adverse childhood events (ACE) using an established screener to evaluate their role in asthma susceptibility and asthma control, including comparisons between urban vs. rural and multi-generational effects in this community-engaged study. We hypothesize that domains of biological and behavioral influences acting on the individual and interpersonal levels generate social stress and have an impact on asthma development and control. Aim 2: Investigate the role of SEF on immunological response to viral respiratory infections (VRIs) in AI children with and without asthma. We will investigate the impact of social and environmental factors measured using validated and Tribally-developed surveys on the immune system of AI children with and without asthma, including response to viral respiratory infections (viral-specific serum IgG and IgM concentrations to RSV and other VRI pathogens known to cause long-term respiratory sequelae). We will quantify serological measurements of participants’ humoral immune responses including serum biomarkers of inflammation (Th1/Th2/Th17 cytokines), atopy (serum total IgE), and total immunoglobulins. We will test our hypothesis that interactions with detailed survey measures of SEF with immunological and clinical outcomes of VRIs, including viral responses in participants with and without asthma are the strongest and most significant predictors in our AI participants. Aim 3: Engage with an existing Tribal Community Advisory Board (CAB) using continuous bidirectional process evaluation to develop an intervention and policy framework of asthma prevention. We will engage with the CRST’s dedicated community and Tribal cultural experts and active volunteers in building our local CAB. We will leverage the scientific knowledge gained under this proposal to work with the CAB to create a sustainable, feasible, and Lakota-driven, intervention and policy framework, including the creation of structures to allow integration of social stressers including ACEs into existing referral services and policy initiatives. We will collect detailed information using questionnaires and semi-structured interviews among CAB members and the community about the study development and processes. We recognize that Tribal children with mild, moderate to severe asthma who are experiencing humoral immune response alterations and a combination of SEFs need very targeted and specialized preventive measures that this study will be able to develop and support with implementation. B. RESEARCH PLAN: Environmental Toxicants and Asthma in American Indian Children Background: Viral respiratory infections in early life have been linked to the development of asthma and persistent respiratory symptoms in children 1–3, including respiratory syncytial virus (RSV) of which the majority of children are exposed before age 2. Infants who develop RSV bronchiolitis in the first year of life have a high chance of developing asthma 4, and children with asthma have an increased risk of experiencing complications and lasting respiratory symptoms from infections such as RSV, SARS-CoV-2, influenza, and rhinovirus-C 5–8. The prevalence of asthma among American Indian (AI) children is 9.3% as compared to 5.5% in non-Hispanic White children 9. This is a serious but understudied, pediatric health disparity in the U.S. that becomes even more pronounced into adulthood, with AI adults having the highest prevalence of asthma as compared to all other racial/ethnic groups 9. Asthma has been linked to a number of social and environmental factors 10–15 including exposure to social stress, tobacco smoke, air pollution, and environmental toxicants including per- and perfluoroalkyl substances (PFAS) 16. There is mounting evidence that PFAS, a “forever chemical” in the environment has a deleterious effect on many aspects of health 17, including thyroid and immune activity 18, inflammation in pregnancy 19, fetal growth 20, immune response to childhood vaccines 21 and viral respiratory infections 22,23. Thus, exposure to PFAS and environmental toxins during childhood may have a lasting effect on Tribal health. In summary, we propose to address newly emerging chemical exposures including PFAS in an at-risk, low income, Native American community in consultation with the Cheyenne River Sioux Tribe (CRST), including children living in Rapid City South Dakota and the Cheyenne River Sioux and Oglala Lakota Reservations. In this area of South Dakota, the proportion of children living below the Federal poverty line is 47% and 57% in Ziebach 24 and Dewey 25 Counties, respectively. The adverse health effects of PFAS and environmental toxins due to community-level exposure in this area of high childhood poverty has yet to be investigated, nor their effects on immunological response to viral respiratory infections and immune dysfunction. Preliminary Research: In the Factors Influencing Pediatric Asthma (FIPA) study we found that AI children with asthma living on the Cheyenne River Sioux and Oglala Lakota Reservations were more likely to reside in multi-unit housing, and in residences with rodent or insect infestation resulting in poor indoor air quality as compared to asthma controls 26. Children with asthma also had higher BMI, total leukocyte counts, % eosinophils, total serum IgE, and specific IgE to five common indoor airborne antigens 27. We also found children with asthma to have lower levels of RSV-specific IgG during the winter (Figure 1) and to report increased hospitalizations and RSV diagnoses (Figure 2), suggesting immune dysregulation with clinical implications 28. We hypothesize that exposures to environmental toxins, some of which have been linked to immune dysregulation may play an important role. Figure 1: A. Asthma cases recruited during the winter (RSV season) had significantly lower RSV IgG as compared to asthma cases recruited during the summer (p=2.5x10-6). There was no observed difference in seasonality for asthma controls (p=0.60). B. More children with asthma have low levels of IgG (<40 IU/mL). In unpublished results, Dr. Erdei (co-PI of parent study) detected PFAS in 83% of samples from 50 CRST adults who fish regularly from the Tribe's main public water sources. She has identified an association between PFAS and a number of tissue- specific and antinuclear autoantibodies, and found serum PFAS and other compounds to be predictors of autoimmune markers indicative of a hyperreactive immune response in adults (Figure 3). Consuming locally caught fish as part of AI Figure 2: Children with asthma in the FIPA study report a higher culture and as a dietary source of protein was also clinical burden from RSV. associated with overall elevation of serum PFAS. Similar investigations among children in the CRST will allow us to learn more about PFAS exposure patterns as it relates to immune dysregulation, viral respiratory infections, and its effect on children’s health in the community. Figure 3: Quantile Regression plots in CRST adults showing that A. Perfluorononanoic acid (PFNA) exposures are predictive of anti- native DNA response. B. PFOS and C. PFOA exposures are predictive of thyroid-specific (anti-thyroglobulin) autoimmune response, with PFOA having an immunosuppressive effect. In summary, we hypothesize that exposure to environmental toxins, specifically PFAS, contributes to immune dysregulation and response to viral respiratory infections in American Indian children with asthma. As recruitment for FIPA2 is starting, this is an opportune time for Dr. Spear to lead a study investigating the role of PFAS and environmental toxins on the health of AI children. This opportunity will afford Dr. Spear to narrow in on the role of PFAS on immune dysregulation and response to viral respiratory infections in children with and without asthma, while making new connections with scientists in the field of environmental research. Overall, our study will advance knowledge of the effect of environmental toxins on immune dysregulation of children to inform future policies and interventions. Thus, our specific aims for this diversity supplement are: Specific Aim 1: Measure and identify suspect and PFAS chemicals that are present in American Indian children from Rapid City and the Cheyenne River Sioux/Oglala Lakota Reservations. Specific Aim 2: Perform correlative and predictive modeling between PFAS/suspect chemicals and immunological biomarkers and response to viral respiratory infections in AI children with and without asthma. Approach: We will perform suspect screening and test for levels of 12 PFAS in serum samples of 52 children with and without asthma and living in urban vs. rural (Reservation) locations (Figure 4). We will identify suspect chemicals present in AI children, and perform preliminary correlations with immune biomarkers, viral-specific immunoglobulins, PFAS and suspect chemicals identified. Characterizing the presence and effect of environmental toxins on the immune system is an essential step for understanding environmental health disparities, which the community has been struggling with for decades. Figure 4: Location and summary of serum samples for study to measure PFAS/suspect chemicals in children ages 6-17 years old in FIPA2. Recruitment is beginning 5/2024. We also have stored samples for >300 original FIPA participants at -80C (living on Reservation, only). Specific Aim 1: Measure and identify suspect and PFAS chemicals that are present in American Indian children from Rapid City and the Cheyenne River Sioux/Oglala Lakota Reservations. We will work with the UCSF Bioassay Facility Core to develop a protocol for PFAS and untargeted suspect screening of serum samples from 52 AI children, including 26 asthma cases and 26 matched controls living in an urban (Rapid City SD) vs. rural (Reservation) environment. Specific Aim 2: Perform correlative and predictive modeling between PFAS/suspect chemicals and immunological biomarkers and response to viral respiratory infections in AI children with and without asthma. We will test for a correlation of PFAS/suspect chemicals with levels of immune biomarkers and viral- specific immunoglobulins. Immune biomarkers will include cytokines, Creactive protein, CBCs (white blood cell counts), total serum IgE, and viral specific IgG/IgM (SARs-CoV2, RSV, influenza, and rhinovirus C). Results from this aim will provide insights in to 1) the variability in exposure to environmental toxicants in children living in urban vs. rural (Reservation) locations and 2) the role of exposure to PFAS/suspect chemicals on immune dysregulation and asthma. Statistical analyses: We will examine the distribution of individual PFAS chemicals plus untargeted suspect chemicals to determine the relevant statistical test. In general, for commonly detected chemicals we will utilize linear and logistic regression models (or nonparametric tests) to test for associations between PFAS/suspect chemicals adjusting for multiple covariates selected through an iterative process (e.g. BMI, sex, household size, asthma medications); we will also contrast models with and without an asthma interaction. For rare chemicals we will apply a fisher’s exact test for detected/undetected. ROC curves will be generated for individual chemicals by asthma and location, and cluster analyses will be performed over all chemicals using a principal component analysis (with UMAP projection) and partial least-squares discriminant analysis (PLS-DA) for predictive modeling and Cox regression. Lastly, we will attempt a mediation analysis to evaluate if exposure to PFAS/suspect chemicals contributes to asthma via immune dysregulation. Relevance to the parent grant: The parent grant is centered on identifying social determinants of the environment including adverse childhood experiences that contribute to the development of asthma through altering the immunological response to viral respiratory infections. However, there is substantial evidence to suggest that exposure to environmental toxicants contribute to immune dysregulation in both the context of asthma and general immune function as discussed above. In this proposal, Dr. Spear will focus on the physical environment, specifically the role of exposure and accumulation of environmental toxicants on immune dysregulation in children with and without asthma.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15484", "attributes": { "award_id": "1R41MD019586-01", "title": "MiREA, a mHealth intervention to Reduce Health Disparities by Improving Equitable Access to Mandated College Students with Problematic Alcohol and Marijuana Use", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 6029, "first_name": "JARRETT AINSWORTH", "last_name": "Johnson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-11-01", "end_date": "2025-10-31", "award_amount": 296519, "principal_investigator": { "id": 32039, "first_name": "Donna Marie", "last_name": "Kazemi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2544, "ror": "", "name": "MHEALTH SYSTEMS, INC", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "This STTR Phase I proposal is designed to address the urgent need for an effective primary prevention approach to the problem of heavy episodic drinking and cannabis misuse among mandated minority college students attending Historically Black Colleges and Universities (HBCUs) and attending school in rural Appalachian Regional Commission (ARC) counties. Alcohol and cannabis misuse affects all demographic groups in the United States (NSDUH, 2021); however, some subsets are disproportionally affected. Access to treatment differs, often by race and gender. With growing evidence of health disparities among minority college students, the COVID-19 pandemic has decimated college budgets and elevated the risk of substance misuse and mental health issues. Smartphone app interventions are expanding and can offer accessible, scalable, and cost-effective tools. Cannabis use has increased significantly among Hispanic and Black Americans aged 18 and up in 2015-2018 (NSDUH, 2020). Alcohol death rates among college-age students (18 to 34) jumped 69% from 2007 to 2020. Cannabis is the most widely used illicit drug among the country's 20- plus million college students. Research suggests that newer technologies, such as smartphone apps, prevent misuse in mandated students more effectively than face-to-face intervention. However, little research has been done into culturally attuned evidence-based interventions that empower students to engage in health-seeking behaviors and avoid risky alcohol and cannabis misuse. To address this gap, mHealth Systems, Inc. is partnering with the University of NC at Charlotte (UNCC), the University of South Carolina USC), and Harvard Medical School Teaching Hospital on this Phase I STTR. We will enhance the Motivational Intervention in Real-time delivered through the Ecological Application (MiREA) App by expanding to incorporate further culturally attuned content. Phase 1 will test the adapted product's feasibility and acceptability. Specific aims: 1) Determine usability, feasibility, and efficacy of the MiREA-AC intervention (months 1-12); we will: a) conduct alpha theater and field testing (months 1-3, n=10) at two U.S. campuses to ensure acceptability of the app's contents; b) conduct a multi-site pilot feasibility trial (months 3-12, n=60) at six U.S. campuses. 2) Examine key customer needs by engaging with a Stakeholders Advisory Board (SAB, n=50, months 1-12) composed of health wellness staff, administrators, and minority representatives from HBCU and ARC socioeconomically disadvantaged colleges and universities and engage the SAB in the integration of MiREA-AC prototype within mandated programs. Participants will include 60 minority-mandated students from six US universities, ages 18 to 25, who have violated school drug and alcohol policies. Because of students' comfort with mobile technologies, we expect those receiving digital intervention to report higher satisfaction with the MiREA-AC mobile app than with in-person interventions. We expect MiREA-AC to be more cost-effective and to have greater reach, adoptability, portability, and sustainability than current approaches.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15488", "attributes": { "award_id": "1I01BX006139-01A1", "title": "Junctophilin- 2 in brown Adipocyte Metabolic Regulation and Obesity", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2024-10-01", "end_date": "2028-09-30", "award_amount": null, "principal_investigator": { "id": 32040, "first_name": "Long-Sheng", "last_name": "Song", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2545, "ror": "https://ror.org/03r9k1585", "name": "Iowa City VA Medical Center", "address": "", "city": "", "state": "IA", "zip": "", "country": "United States", "approved": true }, "abstract": "Obesity, a state of imbalance between caloric intake and energy expenditure, is a major global problem that increases the risk of developing a wide range of diseases including insulin resistance, type 2 diabetes, cardiovascular disease and COVID-19 among others. Brown adipocytes in brown adipose tissue (BAT) depots dissipate chemical energy in the form of heat through non-shivering thermogenesis, to increase systemic energy expenditure and maintain whole-body energy homeostasis in response to stresses, including cold exposure and overnutrition. Brown adipocytes share a common lineage with muscle cells, the source of shivering thermogenesis. We recently discovered that junctophilin-2 (JP2), a muscle specific protein, is also enriched in brown adipocytes. JP2 is a structural protein that spatially organizes endo/sarcoplasmic reticulum (ER/SR)-plasma membrane (PM) junctions in muscle cells. These EM/SR-PM junctions are essential for precise control of Ca2+ homeostasis and contractile function in cardiac and skeletal muscles. In addition to its structural role, we recently demonstrated that JP2 serves as a stress-adaptive transcriptional regulator, controlling the transcriptome that regulates metabolic pathways that are also relevant to adipose metabolism. However, it remains completely unknown whether JP2 also functions in regulating Ca2+ homeostasis, and thermogenic program in brown adipocytes. In pilot studies, JP2 expression in BAT was suppressed by diet-induced obesity. Furthermore, JP2 deficiency disrupts BAT calcium dynamics and blunts sympathetic nervous system activation of thermogenesis in BAT. Notably, adipose-specific JP2 deletion promotes cold intolerance, and worsens obesity-associated metabolic dysfunction. These pilot data indicate that JP2 is required for maintaining thermogenic and metabolic homeostasis in BAT. Based on these intriguing preliminary data, we hypothesize that JP2 is crucial in maintaining normal Ca2+ homeostasis and energy metabolism in brown adipocytes, and defects in JP2-mediated Ca2+ regulation lead to energy imbalance and metabolic dysfunction. To test this hypothesis, we will use a multidisciplinary approach, including multiple novel mouse models, high resolution confocal imaging, patch-clamp electrophysiology, cellular and molecular biology, biochemical analysis and a spectrum of in vitro and in vivo metabolic assays. Upon successful completion of this project, we will establish a mechanistic understanding of the physiological regulation of JP2 in brown adipocytes and the pathophysiological role of JP2 dysregulation in obesity and associated diseases, therefore revealing a novel molecular mechanism leading to metabolic disorders.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15489", "attributes": { "award_id": "75N93024C00014-0-9999-1", "title": "MRNA VACCINE DEVELOPMENT", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-09-01", "end_date": "2026-08-31", "award_amount": 594566, "principal_investigator": { "id": 32041, "first_name": "KATERINA", "last_name": "ANDRIANOVA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2546, "ror": "", "name": "FLAG BIO, INC.", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "The contractor will develop mRNAFlag as a vaccine adjuvant. mRNAFlag is an mRNA transcript that encodes for the deimmunized TLR5 agonist GP532. mRNAFlag would be developed within the context of an influenza mRNA vaccine, using an A/California/07/2009(H1N1) hemagglutinin in an LNP formulation used by Moderna for its SARS-CoV-2 vaccine.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15490", "attributes": { "award_id": "75N91019D00024-0-759102400011-23", "title": "Serological Science for COVID-19 SeroNet", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-09-28", "end_date": "2025-08-30", "award_amount": 180000, "principal_investigator": { "id": 32042, "first_name": "lynn", "last_name": "briscoe", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "In light of the emergence of the novel coronavirus, SARS-CoV-2, and the urgent need to mitigate the pathogen’s spread. There is a crucial need for accurate laboratory-based methods for initial diagnosis, asymptomatic carriage and overall public health understanding of the extent of this disease. The current lack of validated and widely available standardized tests, procedures and reagents for assessment of SARS-CoV-2-specific antibody responses is a critical gap in the rapid response to the SARS-CoV-2 pandemic. a major goal and focus of SeroNet is determining the molecular and cellular components of the immune response to SARS-CoV-2 to understand the innate, humoral and adaptive response, as well as to understand barriers to access", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15491", "attributes": { "award_id": "75N91019D00024-0-759102400011-28", "title": "THE COVID 19 SERVICES CATALYZE TRANSLATIONAL RESEARCH FINDINGS INTO PUBLIC HEALTH CHANGES TO ADDRESS THE NOVEL CORONAVIRUS PANDEMIC THROUGH IMPLEMENTATION OF STANDARDIZED SEROLOGY TESTING FOR ITS INTE", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-09-28", "end_date": "2025-08-30", "award_amount": 420000, "principal_investigator": { "id": 32042, "first_name": "lynn", "last_name": "briscoe", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "The following support shall be provided for Therapeutic Development Branch: • Continuation of the \"Integrated Data Resource for Rare Diseases\" working with Advanced Biomedical Computational Science at Leidos Biomedical Research, Inc.; • Assay validation and non-GMP and GMP manufacturing of batches of drug substance and drug product; • Stability studies to support projects with GMP and / or non-GMP products; • Biodistribution / imaging and pharmacokinetic studies; • Consulting services for development of bioanalytical methods; • Regulatory services to support preclinical and / or clinical-stage projects; • Electron microscopy studies; • Gene expression and proteomic data analyses and cell-based screening studies; • Proteomic profiling, cell-based efficacy studies, and clinical trials for canine comparative oncology; • Laboratory animal support.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15492", "attributes": { "award_id": "1F31HL172636-01A1", "title": "Type 1-2 immune cross-regulation in the lung", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 26342, "first_name": "MARISOL", "last_name": "Espinoza-Pintucci", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-13", "end_date": "2026-09-12", "award_amount": 45909, "principal_investigator": { "id": 32043, "first_name": "Sofia", "last_name": "Caryotakis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 768, "ror": "https://ror.org/043mz5j54", "name": "University of California, San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Respiratory viral infections are a prevalent and ongoing threat to global health, as evidenced by seasonal Influenza A infections and the SARS-CoV-2 pandemic. Notably, the association between allergy and asthma and the severity of respiratory viral illness has been long observed but poorly understood. Group 2 innate lymphoid cells (ILC2s) and the adaptive counterpart Type 2 CD4 helper cells (Th2) have been extensively investigated for their role in allergic inflammation. Our group has described the localization of these type 2 lymphocytes (T2L) in non-lymphoid tissues, such as the lung, at rest and under allergic and mixed type 1-2 inflammation, observing localization near large airways and vessels at rest and expansion to the tissue parenchyma with allergic inflammation. Interestingly, in mixed type 1-2 inflammation, T2L parenchymal distribution is restricted due to Interferon gamma (IFNγ) signaling on T2L. My preliminary data demonstrates that IFNγ-mediated restriction also occurs following viral respiratory infection with Influenza A virus (IAV, PR8) and impacts mouse body weight and lung function. In parallel, I have demonstrated that loss IFNα/β signaling on T2Ls increases body weight loss and impairs lung function in IAV, potentially through a distinct mechanism. These data suggest that IFN-mediated restriction of T2L and T2L topography is critical for appropriate viral clearance and/or tissue repair in viral respiratory infection. Mechanisms of IFN-mediated restriction of T2L have been explored by many groups, including ours, however how this restriction of topography and counter-regulation of T1 immunity by T2L dictate the immune response to viral infection remains elusive. I hypothesize that IFN signaling regulates the topography and function of lung T2Ls in pulmonary viral infections. This proposal will define the topography of T1-T2 cross-regulation in the setting of pulmonary viral infection (Aim 1) and evaluate mechanism of interferon mediated restriction of type 2 lymphocytes (Aim 2). Completion of these aims will elucidate the role of canonical type 1 and type 2 cytokines in mediating tissue resident lymphocyte function in complex inflammation, providing novel mechanistic insight into how topography dictates immunity. Completion of this study provides a foundation for the development of precision therapeutics to selectively regulate lung resident lymphocytes subsets to impact the outcome of diverse lung diseases.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15497", "attributes": { "award_id": "75N92023D00011-0-759202400001-1", "title": "GENETIC EPIDEMIOLOGY OF COPD (COPD GENE) 2024 - 2025 TASK ORDER FOR TASK AREA A: COLLECTION OF COPDGENE STUDY DATA AND BIOSPECIMENS AND OVERSIGHT OF THE COPDGENE STUDY.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-08-10", "end_date": "2025-08-09", "award_amount": 9298220, "principal_investigator": { "id": 32045, "first_name": "JAMES", "last_name": "CAPPO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1553, "ror": "https://ror.org/016z2bp30", "name": "National Jewish Health", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "Genetic Epidemiology of COPD (COPDGene) is a multi-site longitudinal cohort study of current and former smokers to better understand risk factors, natural history, and genetic contributions of chronic obstructive pulmonary disease (COPD) as well as other smoking-related diseases. The purpose of this acquisition is to fund a 15-year follow-up in-person clinical visit (Visit 4) of this cohort, to be re-enrolled from approximately 19 active Clinical Study Centers. A Visit 4 of COPDGene subjects is needed to identify clinical, physiological, imaging, and Omics determinants of COPD and other disease progression in elderly subjects, to assess the impact of COVID-19 on COPD and other disease progression, and to discover determinants of severe COPD development in subjects with preserved ratio, impaired spirometry (PRISm). The acquisition will also support the maintenance of previously collected data and biospecimens, regulatory oversight of the study, and analysis of study data and study biospecimens. The goal of COPDGene is to use extensive longitudinal imaging, physiology, and Omics molecular data in combination with genetics in the COPDGene cohort to identify high-risk subgroups with distinct diagnostic, prognostic, and therapeutic implications. COPDGene has been funded for 15 years through grants and cooperative agreements awarded by NHLBI to National Jewish Health and Brigham and Women’s Hospital. Grant applications for the three Phases of COPDGene [Phase 1: baseline visit (“Visit 1”); Phase 2: five year follow-up (“Visit 2”); Phase 3: ten year follow-up (“Visit 3”)] were all submitted to the parent NIH R01 Funding Opportunity Announcement. Study investigators originally recruited 10,198 current or former smokers in Phase 1. Including nonsmoking controls from both Phase 1 and Phase 2, COPDGene has recruited a total 10,718 subjects all of whom have been extensively phenotyped clinically and radiologically. Additional data collected on these participants include whole genome sequencing as well as RNA sequencing, proteomics, metabolomics, and DNA methylation data from collected blood samples. Investigators have published more than 450 publications, the vast majority of which were peer-reviewed, using COPDGene data. COPDGene also serves as a parent study for many ancillary studies, using public or private funding, a subset of which have collected additional data on all or a subset of participants. COPDGene is overseen by an NHLBI-convened Observational Study Monitoring Board (OSMB). The Visit 4 (15-year follow-up) evaluations will include, where possible, lung function tests (spirometry), questionnaires (including COVID-19 assessment), chest computerized tomography (CT), other functional assessments (e.g., six minute walk distance), and collection and storage of biospecimens from 3,500 of the original 10,718 COPDGene subjects. In addition, this acquisition will support continuation of semi-annual long-term follow-up of the COPDGene cohort and other contact with the cohort as needed, oversight of clinical sites and human subjects protection, maintenance of the database and biobank, continued coordination with NIH and NHLBI data resources, activities relevant to the data management and sharing plan, analysis of data, travel to meetings, and publication costs.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15499", "attributes": { "award_id": "75N95024C00025-0-9999-1", "title": "NCATS CYBERSECURITY SERVICES PROGRAM SUPPORT. POP: 07/29/2024 - 09/18/2024.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-07-29", "end_date": "2024-09-18", "award_amount": 297510, "principal_investigator": { "id": 32046, "first_name": "MARK", "last_name": "BACKUS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "National COVID-19 Cohort Collaborative (N3C): The National COVID-19 Cohort Collaborative (N3C) sponsors the NIH COVID-19 Data Enclave, one of the largest data enclaves in the world supporting COVID-19 research. N3C is a partnership among the NCATS-supported Clinical and Translational Science Awards (CTSA) Program hubs and the NIGMS-supported Institutional Development Award Networks for Clinical and Translational Research (IDeA-CTR), with overall stewardship by NCATS. The N3C program is essentially a medium sized business, consisting of thousands of researchers, requiring enterprise level information technology (IT) support as part of a virtual research organization (VRO). This contract is necessary to ensure that NCATS and N3C can continue to provide adequate support for a secure, collaborative, VRO. This contract allows for continued support of the VRO which supports all of the required information technology functions to support an environment of over 4,000 users, including cloud-based productivity tools, a service desk, commercial and open-source deployments of analytical tools for the community to use, and expansion of the data types available for analysis, such as imaging, viral variant genomic sequences, etc. The common need is to share a collaborative cloud environment capable of ingesting billions of data points and performing a variety of complex analyses against multimodal data types, ranging from pathology and radiology data, synthetic data, genomic information, electronic health records (EHRs) and a wide variety of others. All of this must be done while meeting the highest levels of security and privacy, given the sensitivity of some of the data types being collected and the importance of the work being done in the environment. This contract provides IT security support for all of these enterprise IT efforts.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1391, "pages": 1419, "count": 14184 } } }